Canopy Growth (NASDAQ:CGC) is a leading Canadian cannabis company engaged in the production, distribution and sale of both medical and recreational cannabis products. Headquartered in Smiths Falls, Ontario, the company cultivates a diversified portfolio of offerings that includes dried flower, pre-rolled joints, oils, softgel capsules and edibles. Canopy Growth also markets derivative products such as beverages and wellness formulations under a range of brands, aiming to serve both patient and adult-use markets.
The company operates through multiple subsidiaries, including Tweed Inc., Spectrum Therapeutics and Tokyo Smoke, each targeting distinct consumer segments. Its medical division supplies pharmaceutical-grade cannabis to patients in Canada and select international markets via Spectrum Therapeutics. On the adult-use side, brands like Tokyo Smoke and Doja focus on lifestyle-oriented products and retail experiences. Canopy additionally conducts research into cannabinoids and product formulations to expand its portfolio and address emerging consumer preferences.
Founded in 2013 by Bruce Linton, Chuck Rifici and Neil Belot, Canopy Growth quickly grew through organic expansion and strategic acquisitions. In March 2020, the company appointed David Klein as Chief Executive Officer, entrusting him with the integration of acquired assets and execution of a global growth strategy. Klein brought extensive consumer packaged goods experience, having previously led Constellation Brands’ beverage business in Canada.
Canopy Growth serves markets in Canada and maintains operations or partnerships across Europe, Australia and Latin America. The company has also established a presence in the United States through joint ventures and investments, positioning itself to capitalize on the evolving regulatory landscape. With a focus on innovation, international expansion and brand development, Canopy Growth aims to maintain its leadership in the rapidly changing cannabis industry.
